Senti Biosciences, Inc. (SNTI)

NASDAQ: SNTI · Real-Time Price · USD

3.244

-0.116 (-3.45%)

At close: Apr 1, 2025, 4:00 PM

3.313

+0.068 (2.11%)

After-hours: Apr 1, 2025, 4:42 PM EDT

Senti Biosciences Employees

Senti Biosciences had 34 employees as of December 31, 2024. The number of employees decreased by 14 or -29.17% compared to the previous year.

Employees

34

Change (1Y)

-14

Growth (1Y)

-29.17%

Revenue / Employee

n/a

Profits / Employee

-$1,626,824

Market Cap

84.36M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	34	-14	-29.17%
Dec 31, 2023	48	-74	-60.66%
Dec 31, 2022	122	33	37.08%
Dec 31, 2021	89	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

SNTI News

12 days ago - Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights - GlobeNewsWire
19 days ago - Senti Bio Appoints Feng Hsiung to Board of Directors - GlobeNewsWire
5 weeks ago - Senti Bio Strengthens Leadership Team with Strategic Hires - GlobeNewsWire
3 months ago - Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics - GlobeNewsWire
4 months ago - Senti Biosciences Announces New Employment Inducement Grants - GlobeNewsWire
4 months ago - Why Is Senti Biosciences Stock Surging Over 400% On Monday? - Benzinga
4 months ago - Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing - GlobeNewsWire
4 months ago - Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML - GlobeNewsWire